YU59001A - 16-halogen-epotilon-derivati, postupak za njihovo dobijanje i njihova farmaceutska primena - Google Patents

16-halogen-epotilon-derivati, postupak za njihovo dobijanje i njihova farmaceutska primena

Info

Publication number
YU59001A
YU59001A YU59001A YUP59001A YU59001A YU 59001 A YU59001 A YU 59001A YU 59001 A YU59001 A YU 59001A YU P59001 A YUP59001 A YU P59001A YU 59001 A YU59001 A YU 59001A
Authority
YU
Yugoslavia
Prior art keywords
producing
halogen
epothilone derivatives
pharmaceutical use
derivatives
Prior art date
Application number
YU59001A
Other languages
English (en)
Inventor
Ulrich Klar
Werner Skuballa
Bernd Buchmann
Wolfgang Schwede
Michael Schirner
Original Assignee
Schering Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19908765A external-priority patent/DE19908765A1/de
Priority claimed from DE19954230A external-priority patent/DE19954230A1/de
Application filed by Schering Ag. filed Critical Schering Ag.
Publication of YU59001A publication Critical patent/YU59001A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

16-halogen-epotilon-derivati, postupak za njihovu proizvodnju i njihova farmaceutska primena Predloženi pronalazak opisuje nove epotilon-derivate opšte formule I, u kojima je R8 halogeni atom naročito znači atom fluora ili atom hlora, kao i ostale substituente, koji u opisu imaju navedena značenja. Nova jedinjenja su podesna za proizvodnju lekova.[The invention relates to novel epothilone derivatives of general formula (I), wherein R8 means a halogen atom, especially a fluorine or chlorine atom, and the remaining substituents have the meanings given in the description. The novel compounds are suitable for producing medicaments.
YU59001A 1999-02-18 2000-02-18 16-halogen-epotilon-derivati, postupak za njihovo dobijanje i njihova farmaceutska primena YU59001A (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19908765A DE19908765A1 (de) 1999-02-18 1999-02-18 16-Halogen-Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE19954230A DE19954230A1 (de) 1999-11-04 1999-11-04 16-Halogen-Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung

Publications (1)

Publication Number Publication Date
YU59001A true YU59001A (sh) 2005-07-19

Family

ID=26052117

Family Applications (1)

Application Number Title Priority Date Filing Date
YU59001A YU59001A (sh) 1999-02-18 2000-02-18 16-halogen-epotilon-derivati, postupak za njihovo dobijanje i njihova farmaceutska primena

Country Status (28)

Country Link
US (3) US6610736B1 (sh)
EP (1) EP1150980B1 (sh)
JP (1) JP2002537301A (sh)
KR (1) KR100718616B1 (sh)
CN (1) CN1209360C (sh)
AR (1) AR022636A1 (sh)
AT (1) ATE370946T1 (sh)
AU (1) AU3156700A (sh)
BG (1) BG105802A (sh)
BR (1) BR0008331A (sh)
CA (1) CA2361278A1 (sh)
CZ (1) CZ20012951A3 (sh)
DE (1) DE50014587D1 (sh)
EA (1) EA009206B1 (sh)
EE (1) EE200100431A (sh)
ES (1) ES2291194T3 (sh)
HK (1) HK1044945A1 (sh)
HR (1) HRP20010677A2 (sh)
HU (1) HUP0105478A3 (sh)
IL (1) IL144519A0 (sh)
MX (1) MXPA01008328A (sh)
NO (1) NO20014013L (sh)
NZ (1) NZ513268A (sh)
PL (1) PL349863A1 (sh)
SK (1) SK11852001A3 (sh)
TW (1) TWI285645B (sh)
WO (1) WO2000049021A2 (sh)
YU (1) YU59001A (sh)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2269118C (en) 1996-11-18 2012-05-29 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents
EP1386922B1 (en) 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
EP1847540A1 (de) * 1997-08-09 2007-10-24 Bayer Schering Pharma Aktiengesellschaft Neue Epothilonderivate, Herstellungsverfahren dafür und ihre pharmazeutische Verwendung
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
DE10020899A1 (de) * 2000-04-20 2001-10-25 Schering Ag 9-Oxa-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
AU2002245296B2 (en) * 2001-01-25 2006-12-21 Bristol-Myers Squibb Company Methods of administering epothilone analogs for the treatment of cancer
KR20030071853A (ko) 2001-01-25 2003-09-06 브리스톨-마이어스스퀴브컴파니 에포틸론 유사체를 함유한 비경구용 제제
NZ526871A (en) 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
ATE389401T1 (de) 2001-01-25 2008-04-15 Bristol Myers Squibb Co Verfahren zur herstellung von pharmazeutischen zusammensetzungen enthaltend epothilon-analoga zur krebsbehandlung
CA2438598A1 (en) 2001-02-20 2002-08-29 Francis Y. F. Lee Epothilone derivatives for the treatment of refractory tumors
IL156988A0 (en) 2001-02-20 2004-02-08 Bristol Myers Squibb Co Pharmaceutical compositions containing epothilone derivatives
PL368973A1 (en) 2001-03-14 2005-04-04 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
CA2449077A1 (en) 2001-06-01 2002-12-12 Gregory D. Vite Epothilone derivatives
WO2003026744A1 (en) * 2001-09-25 2003-04-03 Alcon, Inc. The use of epothilones and analogs in conjunction with ophthalmic surgery
EP1340498A1 (en) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Use of epothilones in the treatment of brain diseases associated with proliferative processes
AU2003218107A1 (en) 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
SI1483251T1 (sl) 2002-03-12 2010-03-31 Bristol Myers Squibb Co C cian epotilonski derivati
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
AU2003243561A1 (en) 2002-06-14 2003-12-31 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
MXPA05002113A (es) * 2002-08-23 2005-06-03 Sloan Kettering Inst Cancer Sintesis de epotilonas, intermediarios para ellas, analogos y usos de los mismos.
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
RU2311415C2 (ru) * 2002-08-23 2007-11-27 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч Синтез эпотилонов, их промежуточных продуктов, аналогов и их применения
AU2003275068B2 (en) 2002-09-23 2009-09-17 Bristol-Myers Squibb Company Methods for the preparation, isolation and purification of epothilone B, and X-Ray crystal structures of epothilone B
EP1559447A1 (en) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
JP2008520696A (ja) * 2004-11-18 2008-06-19 ブリストル−マイヤーズ スクイブ カンパニー イキサベピロンを含む腸溶性被覆ビーズおよびその製造
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
CN101535492A (zh) 2005-02-11 2009-09-16 南加州大学 表达含有二硫键的蛋白质的方法
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
US20070014978A1 (en) * 2005-07-18 2007-01-18 Anthony Poloso Method of flame blocking and articles made therefrom
EP2029156A4 (en) * 2006-05-01 2010-07-21 Univ Southern California POLY THERAPY FOR TREATING CANCER
CN101535300B (zh) 2006-05-16 2014-05-28 埃格拉医疗公司 Iap bir域结合化合物
EP2065054A1 (en) * 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
EP2070521A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Surface-modified nanoparticles
WO2010056901A2 (en) 2008-11-13 2010-05-20 University Of Southern California Method of expressing proteins with disulfide bridges with enhanced yields and activity
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
CN102985439B9 (zh) 2010-02-12 2016-08-03 制药科学股份有限公司 Iap bir结构域结合化合物
US9717803B2 (en) 2011-12-23 2017-08-01 Innate Pharma Enzymatic conjugation of polypeptides
US10132799B2 (en) 2012-07-13 2018-11-20 Innate Pharma Screening of conjugated antibodies
WO2014072482A1 (en) 2012-11-09 2014-05-15 Innate Pharma Recognition tags for tgase-mediated conjugation
EP2968582B1 (en) 2013-03-15 2020-07-01 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
WO2014202773A1 (en) 2013-06-20 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
JP6744212B2 (ja) 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． ポリペプチドの酵素的結合
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2685521B2 (ja) 1988-08-05 1997-12-03 株式会社日立製作所 車両用換気装置
EP0353732A3 (de) * 1988-08-05 1991-11-06 Ciba-Geigy Ag Neue Fluorolefine, Verfahren zu deren Herstellung und deren Verwendung
IE904673A1 (en) * 1989-12-27 1991-07-17 Monsanto Co Substituted pyridine compounds
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
EP1847540A1 (de) * 1997-08-09 2007-10-24 Bayer Schering Pharma Aktiengesellschaft Neue Epothilonderivate, Herstellungsverfahren dafür und ihre pharmazeutische Verwendung
WO2000000485A1 (de) * 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
DE10020517A1 (de) * 2000-04-19 2001-10-25 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung

Also Published As

Publication number Publication date
EP1150980B1 (de) 2007-08-22
JP2002537301A (ja) 2002-11-05
KR100718616B1 (ko) 2007-05-16
DE50014587D1 (de) 2007-10-04
ES2291194T3 (es) 2008-03-01
US6610736B1 (en) 2003-08-26
NZ513268A (en) 2004-05-28
ATE370946T1 (de) 2007-09-15
NO20014013L (no) 2001-10-18
BR0008331A (pt) 2002-01-29
WO2000049021A3 (de) 2000-12-28
SK11852001A3 (sk) 2002-04-04
EE200100431A (et) 2002-12-16
EA200100826A1 (ru) 2002-02-28
CN1341115A (zh) 2002-03-20
BG105802A (bg) 2002-03-29
TWI285645B (en) 2007-08-21
CA2361278A1 (en) 2000-08-24
HUP0105478A2 (en) 2002-06-29
AU3156700A (en) 2000-09-04
PL349863A1 (en) 2002-09-23
HUP0105478A3 (en) 2002-08-28
HK1044945A1 (en) 2002-11-08
WO2000049021A2 (de) 2000-08-24
NO20014013D0 (no) 2001-08-17
HRP20010677A2 (en) 2005-06-30
KR20010102215A (ko) 2001-11-15
EA009206B1 (ru) 2007-12-28
IL144519A0 (en) 2002-05-23
CN1209360C (zh) 2005-07-06
MXPA01008328A (es) 2002-06-04
EP1150980A2 (de) 2001-11-07
AR022636A1 (es) 2002-09-04
CZ20012951A3 (cs) 2001-11-14
US20040014978A1 (en) 2004-01-22
US20050187270A1 (en) 2005-08-25
US6930102B2 (en) 2005-08-16

Similar Documents

Publication Publication Date Title
YU59001A (sh) 16-halogen-epotilon-derivati, postupak za njihovo dobijanje i njihova farmaceutska primena
JO2353B1 (en) New derivatives of mixed-ring fluoroglycosides and drugs containing these compounds and their use
MY139303A (en) Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
MY136430A (en) N-adamantylmethyl derivatives, pharmaceutical compositions containing them and processes for their preparation
HK1062888A1 (en) Vinyl phenyl derivatives as glk activators
WO2001046200A8 (en) Novel piperidine and piperazine derivatives
BG108318A (en) Carboxamide-substituted phenylurea derivatives and method for the production and use thereof as medicaments
TNSN05194A1 (en) Substituted n-arylheterocycles, method for production and use thereof as medicaments
TNSN04199A1 (en) Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use
MXPA03010201A (es) Derivados de 2-piridin-ciclohexan-1,4-diamina sustituidos.
ATE316083T1 (de) Adamantanderivate
SE0104140D0 (sv) Novel Compounds
MXPA04001307A (es) Compuestos biciclicos aromaticos sustituidos con aminoalquilo, metodo para la produccion de los mismos y su uso como farmacos.
DE60204452D1 (de) Pyrazolo[1,5]pyridinderivate
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
SE9901875D0 (sv) Novel compounds
GB0415365D0 (en) Pyrimidine derivatives
MXPA04001968A (es) Agentes antidiabeticos.
GB0109122D0 (en) Novel compounds
IL165558A0 (en) N-benzoylureidocinnamate derivatives method for production and use thereof
IL166057A0 (en) Urea-substituted and urethane-substituted acylureas methods for the production thereof and their useas medicaments
NZ545580A (en) Aminoquinoline derivatives and their use as adenosine A3 ligands
WO2000063219A8 (en) Platinum complexes for the treatment of cancer
NZ515108A (en) Novel ribose-substituted aromatic amides, method for the production and use thereof as medicaments
RS88704A (en) Acyl-3-carboxyphenylurea derivatives, method for production and use thereof